Timber Pharmaceuticals Valuation
| TMBRDelisted Stock | USD 1.72 0.01 0.58% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Timber Pharmaceuticals has a current Real Value of $1.53 per share. The regular price of the company is $1.72. Our model measures the value of Timber Pharmaceuticals from inspecting the company fundamentals such as Return On Equity of -3.43, shares outstanding of 3.43 M, and Shares Owned By Institutions of 7.78 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Timber Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Timber Pharmaceuticals is based on 3 months time horizon. Increasing Timber Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Timber stock is determined by what a typical buyer is willing to pay for full or partial control of Timber Pharmaceuticals. Since Timber Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Timber Stock. However, Timber Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.72 | Real 1.53 | Hype 1.72 | Naive 1.63 |
The intrinsic value of Timber Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Timber Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Timber Pharmaceuticals helps investors to forecast how Timber stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Timber Pharmaceuticals more accurately as focusing exclusively on Timber Pharmaceuticals' fundamentals will not take into account other important factors: Timber Pharmaceuticals Total Value Analysis
Timber Pharmaceuticals is at this time forecasted to have valuation of (916.94 K) with market capitalization of 1.18 M, debt of 331.15 K, and cash on hands of 11.22 M. The negative valuation of Timber Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Timber Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(916.94 K) | 1.18 M | 331.15 K | 11.22 M |
Timber Pharmaceuticals Investor Information
The company recorded a loss per share of 1.97. Timber Pharmaceuticals last dividend was issued on the 19th of May 2020. The entity had 1:50 split on the 9th of November 2022. Based on the key indicators related to Timber Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Timber Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Timber Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Timber Pharmaceuticals has an asset utilization ratio of 0.81 percent. This connotes that the Company is making $0.008094 for each dollar of assets. An increasing asset utilization means that Timber Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Timber Pharmaceuticals Ownership Allocation
About 91.11 % of Timber Pharmaceuticals outstanding shares are held by general public with 1.11 (%) owned by insiders and only 7.78 % by institutional holders.Timber Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 83.18 K. Net Loss for the year was (19.38 M) with loss before overhead, payroll, taxes, and interest of (5.26 M).About Timber Pharmaceuticals Valuation
The delisted stock valuation mechanism determines Timber Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Timber Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Timber Pharmaceuticals. We calculate exposure to Timber Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Timber Pharmaceuticals's related companies.Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey. Timber Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people.
Timber Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Timber Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.1 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Timber Stock
If you are still planning to invest in Timber Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Timber Pharmaceuticals' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |